| Name | Title | Contact Details |
|---|
Fountainworks Consulting is a Raleigh, NC-based company in the Business Services sector.
Vermont (/vərˈmɒnt/) is a state in the New England region of the United States.
Kabat Schertzer De La Torre Taraboulos & Co. provides a full range of professional, technical, consulting, and business services to clients in a wide range of industries. We continually provide innovative solutions for our clients to help them achieve their personal and business financial goals. We are dedicated to serving our clients` total financial needs. We take pride in the total commitment to provide valuable professional services in a timely, efficient manner while maintaining the highest level of quality and value in the professional services that we provide. A concentrated effort is made to service all of a client`s needs - both those requested by the client and those needed but unrecognized. We consider ourselves to be a part of a client`s team, which plans strategies that will insure the success of their business and personal goals. By listening to clients describe the concerns and challenges they face everyday, we try to formulate a plan to take advantage of new opportunities and help find acceptable solutions to current challenges.
B&T Enterprises supplies products and services to fire departments, recreational and commercial divers, paint ball facilities and industrial facilities.
Cellerant Therapeutics is a clinical stage biotechnology company focused on developing human stem cell and antibody therapies for oncology applications and blood-related disorders. Cellerant`s programs include: CLT-008, an off-the-shelf cellular immunotherapy, under evaluation in a multicenter, open-label, randomized, controlled Phase 2 clinical trial in patients with de novo AML; CSC030-ADC, a preclinical monoclonal antibody drug conjugate that selectively targets and kills leukemic stem and blast cells responsible for initiating and maintaining disease; and CSC012, a preclinical monoclonal antibody targeting leukemic and pre-leukemic stem cells for acute leukemias and myelodysplastic syndromes. The Company is also developing next generation CAR product candidates leveraging its proprietary immunocellular therapy and antibody discovery and development platform.